EASL (European Association for the Study of the Liver)

Published on 27/05/2019

10-14 April, 2019
Vienna, Austria

ENYO Pharma team was present in Vienna from the 10th to the 14th of April at the EASL congress on liver diseases. On this occasion, several and fruitful discussions with various players took place. It was also the opportunity to present, in collaboration with the French research institut Inserm, a poster on the role of FXR and FXR agonists in the recruitment of HBx protein on HBV DNA.

Read next in 'Events'

• The 2024 international workshop on Alport syndrome
• ENYO Pharma annonce un financement de Série C de 39 millions d'euros et l’autorisation de la FDA (IND) pour tester Vonafexor dans un essai clinique de Phase 2 pour les patients atteints du syndrome d'Alport
• 6th CKD Summit – Chronic Kidney Disease Drug Development
• ASN Kidney Week
• Alport Connect 2023, the annual Alport syndrome patient and family meeting in US